Dr Graff talks about how the CLL treatment landscape has evolved in recent yearss.
Dr Goy shares highlights of recent innovations in the treatment of patients with MCL.
Dr Richardson discusses his study on the use of melphalan flufenamide plus dexamethasone for the treatment of relapsed/refractory MM.
Estefania Labanca, PhD, discusses data on CRPC progression and the use of non-canonical AR signaling and ketone body fuel which were presented at the AACR Annual Meeting.
Dr Grover discusses the background and findings of her study on anti-CD30 CAR-T therapy for patients with relapsed/refractory Hodgkin lymphoma.
Yuan Zhang, PhD, and Yi Xiao, PhD, discuss boosting immune surveillance with low-dose PI3K inhibitors to facilitate early intervention of breast cancer.
Xiuning Le, MD, PhD, discusses results from the ZENITH20 trial, which showed that twice daily poziotinib improved AEs and retained anti-tumour activity in EGFR+ or HER2+ NSCLC.
Leigh Ellis, PhD, discusses efforts of Cedars-Sinai researchers to discover new ways to alter tissues surrounding prostate tumors to help the body fight cancer.
Ivana Bozic, PhD, highlights her study which evaluated the efficacy of patient preconditioning in the context of CAR T-cell therapy.
Niamh Coleman, MD, PhD, discusses data on whole exome sequencing (WES) of tumor tissue and ctDNA in GIST, presented at the AACR Annual Meeting.
Stay in the know.
OncNet Newsletter